🗞️ News from AUGIS 2024 Scientific Meeting last week! RefluxStop™ outcomes data was presented by Dr. med. Moustafa Elshafei from a study of 158 patients. The Topic: Pooled two-year results of the novel RefluxStop implantable device in management of gastroesophageal reflux disease in Germany: Retrospective Analysis. The Results: A 90.9% improvement in GERD-HRQL score, a patient-reported measure of quality of life, was seen after having the RefluxStop™ procedure. The Data: Collected by two of Germany's top anti-reflux surgeons at renowned facilities, Dr. med. Moustafa Elshafei of Krankenhaus Nordwest GmbH in Frankfurt, and Dr. med. Thorsten Lehmann of Klinikum Friedrichshafen in Friedrichshafen, Germany. ✏️ The Abstract: Found on page 3 at this link- https://lnkd.in/g-e3M6kt ✏️ The Press Release: https://lnkd.in/geEtCpZT
Implantica
Herstellung medizinischer Geräte
Implantica is a MedTech group dedicated to bringing advanced technology into the body. #SwissTech #DigitalHealth
Info
Implantica is a MedTech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
- Website
-
http://www.implantica.com
Externer Link zu Implantica
- Branche
- Herstellung medizinischer Geräte
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Zug
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2003
- Spezialgebiete
- Medical Devices, Smart Medical Implants, eHealth, Medical Technology, Digital Health, MedTech, Health Technology und Gastroenterology
Orte
-
Primär
Industriestrasse 24
Zug, 6300, CH
-
Deutschland, DE
-
Italien, IT
-
Spaniem, ES
Beschäftigte von Implantica
Updates
-
RefluxStop® data can be found in a handful of recently published studies including 4-Year results! Read all about it at the links below. 1. Treating acid reflux without compressing the food passageway: 4-year safety and clinical outcomes with the RefluxStop device in a prospective multicenter study, Implantica CE Study https://lnkd.in/gxvJR_-d 2. Multicentric short term and safety study of ineffective esophageal motility patients treated with RefluxStop device https://lnkd.in/g2G3kmxM 3. Exploring the feasibility and safety of laparoscopic anti-reflux surgery with the new RefluxStop device: a retrospective cohort study of 40 patients https://lnkd.in/gEk-yHvT 🚀 Heading to #AFS2024 this month? Be sure to stop by our booth for lively discussion and learning with the RefluxStop® Clinical Team!
-
A recently published study shows the clinical benefits of RefluxStop™ as a treatment for chronic GERD with only a minor budgetary impact to the Italian healthcare system. The study, "The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System," was published this week in PharmacoEconomics Journal, see it here: https://lnkd.in/gceNVXqG #GERD #AntiReflux
-
🚀 It's always exciting to see independent surgeons choose to collect data and report on RefluxStop® outcomes. The abstract, "Safety and Quality-of-Life Outcomes Following Surgery with the RefluxStop Device for Gastroesophageal Reflux Disease: Pooled 1-Year Data from Two Large Hospitals," (both hospitals located in Switzerland) will be presented at the American Foregut Society Annual Meeting by Prof. Dr. Joerg Zehetner. Presentation: Saturday, September 28, 12:00-12:10 PM. Will we see you there? Add this session to your calendar: https://lnkd.in/gpeikGJF
-
☎️ London Calling! ☎️ RefluxStop™ is heading to London for the European Foregut Society 2024 Annual Meeting! Will we see you there? Today is a great day to reserve your spot: https://lnkd.in/dErBJF9k *RefluxStop™ is not available for sale in the US and Canada. Contact Implantica for availability in your region. [email protected]
-
Coming to the American Foregut Society 2024 Annual Meeting! Register for the RefluxStop® by Implantica Product Theater on Saturday, September 28, 12:30 - 2 pm: https://lnkd.in/ezReyMhb Learn more about this innovative surgical procedure and its outcomes in Europe! #AFS2024 #BetterTogether
-
Implantica hat dies direkt geteilt
Thank you to Implantica for this post about RefluxStop ™ , a revolutionary implant designed to prevent acid reflux by restoring the lower oesophageal valve to its natural position. This non-invasive device offers a promising solution for GORD patients, reducing symptoms and the need for lifelong medication. #heartburn #GORD #reflux #medicalresearch
We're always inspired to see stories that include RefluxStop™, like this one from The Independent: https://lnkd.in/gC58v8yJ
-
👋 Heading to the American Foregut Society Annual Meeting? See us at the welcome reception! Welcome Reception 🎉 Thursday, September 26, 6-9pm The RefluxStop® Clinical Team will be on hand for education and dialogue about this innovative treatment for GERD used in Europe. In the meantime, see 4-Year results in this study published in August in Surgical Endoscopy Journal: https://lnkd.in/gxvJR_-d #AFS2024 #BetterTogether
-
We're always inspired to see stories that include RefluxStop™, like this one from The Independent: https://lnkd.in/gC58v8yJ
-
✴️ Over a Billion people worldwide suffer from GERD¹ and medication doesn't always work, symptoms persist in up to 40% of patients treated with PPI's.² ³ About 10-20% of GERD patients develop pre-cancerous changes⁴ so it's critical to find effective treatment. ✴️ Even if medication does work, long-term safety of PPI use is increasingly scrutinized and associated with several negative side effects including an increased risk of pancreatic cancer.⁵ ➡️ See the article: https://lnkd.in/eB6-P5Qn. ✴️ If medication is not the answer, could GERD patients benefit from a referral for a surgical consult? ✴️ For more patients than ever, that answer is yes. The RefluxStop™ does not encircle the food passageway making it a possible solution for many patients who previously may not have been considered for surgery. ➡️ Read the latest on RefluxStop™ at the Implantica Scientific Publications & Abstracts Page: https://lnkd.in/gp3vGV3Y 1. Nirwan, J.S., Hasan, S.S., Babar, ZUD. et al. Global Prevalence ad Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis. Sci Rep 10, 5814 (2020). 2. El-Serag, H.B., Becher, A. & Jones, R Aliment Pharmacol. Ther. 32, 720-737 (2010) 3. Kahrilas, P.J. et al. Clin. Gastroenterol. Hepatol. 10, 612-619 (2012) 4. Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am. 2015;44(2):203-231. 5. Brusselaers N, Sadr-Azodi O, Engstrand L, Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden, J Gastroenterol. 2020; 55(4): 453–461